Paper Details

  1. Home
  2. Paper Details

Safety and Side Effects of Rifampin versus Isoniazid in Children.

Author: AdjobimeyMenonli, AprianiLika, BenedettiAndrea, DialloThierno, ElwoodKevin, FregoneseFederica, GninafonMartin, HillPhilip C, HornbyKaren, LiPei-Zhi, LongRichard, MarksGuy B, MenziesDick, Obeng BaahJoseph, RuslamiRovina, SchwartzmanKevin, SowOumou, TrajmanAnete, ValiquetteChantal, WulandariDiah A, ZielinskiDavid

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Equivalence TrialA clinical trial designed to show that a new treatment is equivalent in efficacy/safety to an existing treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Treating latent tuberculosis (TB) infection in children is important because it can turn into a serious illness. The current standard treatment, nine months of isoniazid, has problems with people not taking their medication and side effects. A shorter four-month treatment with rifampin has been shown to be safer and have better completion rates in adults.
Paper Details　
Original Abstract of the Article :
The treatment of latent infection with Mycobacterium tuberculosis is important in children because of their vulnerability to life-threatening forms of tuberculosis disease. The current standard treatment - 9 months of isoniazid - has been associated with poor adherence and toxic effects, which have ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1714284

データ提供：米国国立医学図書館（NLM）

Rifampin vs. Isoniazid in Children: A Battle Against TB

This study delves into the fight against tuberculosis, a disease that can be particularly dangerous for children. It explores the effectiveness and safety of two different medications used to treat latent tuberculosis infection: rifampin and isoniazid. It's like a duel between two skilled warriors in a desert oasis, each with their own strengths and weaknesses. The authors found that rifampin, a 4-month treatment, proved to be safer and more effective than isoniazid, the traditional 9-month treatment, in adults. They are now applying this knowledge to children, looking for a solution to this challenging problem. This research is like a desert traveler searching for the best route to a distant oasis—finding the most efficient and safe path for treating this potentially devastating disease.

Rifampin Offers Hope for Children with TB

The study showed that rifampin, a shorter and potentially safer treatment, could be a game-changer for treating children with latent tuberculosis. This is like finding a hidden spring in the desert—a source of relief and hope. The results suggest that rifampin could help improve adherence to treatment, a crucial factor for success in fighting tuberculosis. This research could lead to better outcomes for children with tuberculosis, a significant victory in this fight.

Choosing the Right Treatment for Children

This research highlights the importance of careful consideration when choosing a treatment for children with tuberculosis. It's like navigating a treacherous sandstorm—the right approach can make all the difference. The study emphasizes the need for tailored treatments based on individual factors, including age and potential risks. This research could pave the way for more effective and less burdensome treatment options for children battling tuberculosis.

Dr.Camel's Conclusion

This research is a testament to the ongoing quest to find better treatments for infectious diseases. It's like a journey through a desert landscape—a constant search for solutions and innovations. The study underscores the importance of finding treatments that are not only effective but also safe and well-tolerated, particularly for vulnerable populations like children.

Date :
  1. Date Completed 2018-08-10
  2. Date Revised 2018-08-10
Further Info :

Pubmed ID

30067928

DOI: Digital Object Identifier

10.1056/NEJMoa1714284

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.